CARsgen® is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The Company has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production.
CARsgen® has developed a competitive product pipeline with global rights, featuring nine CAR T-cell products. Among them, zevorcabtagene autoleucel (“zevor-cel” or “CT053”), an autologous B-cell maturation antigen (BCMA) CAR T-cell therapy, has been approved in China. Another key product candidate, satricabtagene autoleucel ("satri-cel" or "CT041"), is an autologous CAR T-cell therapy targeting Claudin18.2. Satricabtagene autoleucel is expected to be the first CAR T-cell therapy for solid tumors to file for a New Drug Application. In addition to its autologous products, CARsgen® is also advancing differentiated allogeneic CAR T-cell therapies.
To address major challenges of CAR T-cell therapies, CARsgen® has also developed novel technologies and platforms, including:
1) THANK-uCAR® (Target and Hinder the Attack of NK cells on Universal CAR) — differentiated allogeneic CAR-T platform, enhances proliferation and persistence of the allogeneic CAR T cells;
2) CARcelerate® — one-day culture, produces CAR T cells that are younger;
3) CycloCAR® (Cytokine and Chemokine Loaded CAR) — enhance efficacy in solid tumors;
4) LADAR® (Local Action Driven by Artificial Receptor) — a versatile platform for precise targeting.
CARsgen® has established in-house, vertically integrated manufacturing capabilities for the three key stages of CAR T manufacturing, including the production of plasmids, lentiviral vectors, and CAR T cells. The company has established commercial manufacturing facilities in China and the United States to support clinical trials and commercial manufacturing. With the commercial GMP manufacturing facility in Jinshan, Shanghai, we manufacture CAR T-cell products in-house to support clinical trials in China and manufacture the lentiviral vectors in-house to support clinical trials globally. Our GMP manufacturing facility in Durham, North Carolina (“RTP Manufacturing Facility”) will support clinical studies and early commercial launch in the United States, Canada and Europe.
The company's diverse team of experts collaborates across borders to advance the development of CAR T-cell therapies and ensure that they meet the needs of patients around the world.
CARsgen’s mission is to become a global biopharmaceutical leader that provides innovative and differentiated cell therapies for cancer patients worldwide and makes cancer curable.